Clinical Trial Update: A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of MLN0128 in metastatic anaplastic thyroid cancer and poorly differentiated or radioiodine-refractory differentiated thyroid cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Differentiated Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• MLN0128 (sapanisertib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-12